35Pharma

Montreal, Canada · Founded 2021 · Acquired/Merged (Operating Subsidiary)

Operator of a biopharmaceutical company intended for pulmonary hypertension and musculoskeletal disorders. 35Pharma is based in Montreal, Canada and was founded in 2021. Its last known valuation is $950 million (Apr 2026). It has raised $70 million.

Last price · $/share
—
Implied valuation
$950.0M
Total raised
$70.0M
Last round
—
What is 35Pharma worth?
$950.0Mlast known valuation
Free account
More of 35Pharma with a free account
  • ·Watch 35Pharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

35Pharma funding history

No rounds on record

No funding rounds for 35Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

35Pharma valuation

35Pharma's last known valuation is $950 million, from Apr 2026. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How 35Pharma's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For 35Pharma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about 35Pharma

What is 35Pharma worth?
35Pharma's last known valuation is $950.0M.
How much has 35Pharma raised?
35Pharma has raised $70.0M in total funding across its recorded rounds.